Ermeza is a drug owned by Mylan Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2035. Details of Ermeza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9345772 | Liquid levothyroxine formulations |
Feb, 2035
(10 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Ermeza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ermeza's family patents as well as insights into ongoing legal events on those patents.
Ermeza's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ermeza's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 27, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ermeza Generic API suppliers:
Levothyroxine Sodium is the generic name for the brand Ermeza. 16 different companies have already filed for the generic of Ermeza, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ermeza's generic
Alternative Brands for Ermeza
There are several other brand drugs using the same active ingredient (Levothyroxine Sodium) as Ermeza. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Azurity |
| ||
| Cediprof Inc |
| ||
| Fresenius Kabi Usa |
| ||
| Genus Lifesciences |
| ||
| Hikma |
| ||
| Ibsa |
| ||
| Inst Biochimique |
| ||
| King Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Levothyroxine Sodium, Ermeza's active ingredient. Check the complete list of approved generic manufacturers for Ermeza
About Ermeza
Ermeza is a drug owned by Mylan Pharmaceuticals Inc. Ermeza uses Levothyroxine Sodium as an active ingredient. Ermeza was launched by Mylan in 2022.
Approval Date:
Ermeza was approved by FDA for market use on 29 April, 2022.
Active Ingredient:
Ermeza uses Levothyroxine Sodium as the active ingredient. Check out other Drugs and Companies using Levothyroxine Sodium ingredient
Dosage:
Ermeza is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MCG/5ML | SOLUTION | Prescription | ORAL |